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UkraineAbstract Background: Prescription and administration of drugs are still carried out without
taking into consideration the individual’s needs of a particular patient on the post-Soviet territory.
A pharmacist may play a crucial role in the ﬁeld of pharmacogenetics development in any country,
nevertheless his/her role is uncertain even in the countries where pharmacogenetics is intensively
developed. The aim of the present work is to analyze students’ awareness about pharmacogenetics
in the National University of Pharmacy (NUPh) since its development is delayed in Ukraine.
Methods: Field investigations have been used in this work. The material analysis based on
questioning 637 students of the 1st–4th year majoring in pharmacy has been carried out.
Results: The analysis of the future pharmacists’ awareness in the ﬁeld of genetics and pharma-
cogenetics, as well as the study of the sex speciﬁcity of this awareness, has been carried out for the
ﬁrst time in Ukraine. It has been stated that more than 70% of the students questioned got the
information about pharmacogenetics in University for the ﬁrst time. However, only more than
one-third of respondents (37.7% of males and 43.9% of females) correctly understand the idea
of this discipline. About half of the students questioned thought that pharmacocorrection of hered-
itary diseases was impossible. It has been shown that on the whole females were more informed
about pharmacogenetics than males. So, they can become more active persons of pharmaceutical
market in future.
Conclusion: The awareness about pharmacogenetics and its role in personalized medicine is not
satisfactory both in Ukraine and other countries. Thus, it is necessary to pay more attention to the
aspects of pharmacogenetics when training competent up to date specialists in the ﬁeld of
pharmacy. Effective development of the appropriate infrastructure in pharmacogenetics testing
and its introduction among the population of Ukraine are also necessary.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Unfortunately, prescription and administration of drugs are
still carried out without taking into consideration the individ-
ual’s needs of a particular patient on the post-Soviet territory.
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medicine are intensively carried out in the western world.
The problem of the individual’s approach to treatment is
crucial in modern medicine. It is connected with the range of
important discoveries in the ﬁeld of molecular mechanisms
of drug action. These discoveries are related to the levels of
pharmacodynamics (receptors) and pharmacokinetics
(enzymes). A series of new interdisciplinary subjects appeared
not known so far, such as pharmacogenetics, pharmacogenom-
ics, pharmaceutical biotechnology, etc. Thus, it is necessary to
develop educational programs for pharmaceutical and medical
students, as well as for specialists in advanced training, who
work in the health care system [1]. The mentality changes of
a future pharmacist and his/her adaptation to biological
introduction, particularly genetic novation, are needed. There
is a positive experience of interaction between geneticists,
clinicians and pharmacists though it is rather insufﬁcient.
Pharmacogenetics studies interindividual differences in
relation to drugs due to genetic variation between people
and, therefore, it is an important part of personalized medi-
cine. Relevancy of pharmacogenetic tests is obvious due to
occurrence of adverse reactions when underestimating the
genetic polymorphism system, including variations in drug
metabolism. For example, Holland scientists showed that in
39.5% cases adverse reactions appeared as a result of genetic
factors, and the necessity of genetic expertise was initiated
directly by the medical staff [2]. Adverse reactions due to
genetic variations are particularly obvious in cancer patient
treatment [3], and in recent years pharmacogenetic informa-
tion is intentionally included into speciﬁcations of common
drugs. Thus, the Food and Drug Administration takes into
control this procedure in the USA [4]. The examples of drugs
labeled with pharmacogenetics information include cytostatics
6-mercatopurine and irinotecan [5]. The personalized adminis-
tration of drugs has become the applied aspect of the analysis
results of human genetic polymorphism. There are some
perquisites for gradual introduction of pharmacogenetic tests
and genetic passports as a pharmaceutical service. Among
them there is decoding of the human genome [6], and, conse-
quently, understanding of genetic inﬂuence on drug metabolic
pathways in the body.
The main and wide spread type of pharmacogenetic poly-
morphism is SNP (single nucleotide polymorphism). It studies
differences in genetic material of DNA separate nucleotides
(adenine, thymine, guanine and cytosine). SNP occurs in the
human genome practically over each 300–400 b.p. Less signif-
icant are STRs (short tandem repeat), VNTRs (variable num-
ber tandem repeat) and other types of genetic polymorphism.
Interpopulation pharmacogenetic polymorphism is more pro-
nounced, especially, between the individuals of different races
and ethnic groups. The differences between individuals within
a population may also be quite obvious and clinically signiﬁ-
cant due to possibility of adverse reaction development
because of either variations in pharmacodynamics or pharma-
cokinetics. A great number of papers are devoted to polymor-
phism of enzyme gene CYP2D6, which takes part in
metabolism of many drugs, including narcotic analgesics and
antidepressants. For example, the role of CYP2D6 in codeine
metabolism is well-known. A person who doesn’t have potency
of this enzyme (a poor metabolizer), practically doesn’t feel the
analgesic effect of codeine, while ultra-rapid metabolizers are
subjected to serious opioidergic effects, even to lethaloutcomes [7]. It has been shown that in some populations
not less than 50% of people can have at least one of two alleles
of CYP2D6 with the reduced functional activity, which pre-
vents codeine turning into active metabolite morphine and
makes codeine analgesia ineffective [8]. CYP2D6 polymor-
phism also predetermines the therapeutic effect of oxycodone
and hydrocodone [9]. SNP-genotyping of patients receiving
tramadol as a post-operative analgesic in one of the Asian
populations showed that 27% of them were moderate,
70% – quick and 2.9% – ultra-rapid metabolizers. Neverthe-
less the proﬁles of adverse reactions in different groups
signiﬁcantly differed. The widespread alleles were CYP2D6*1
and CYP2D6*10 [10].
Pharmacogenetics suggests three possible areas of activity:
(1) development of methods and identiﬁcation of areas of
research, (2) evaluation of pharmacogenetic tests in clinical
practice, and (3) conducting educational activities and infra-
structure development for the pharmacogenetic test introduc-
tion [11].
The main role in pharmacists’ competence to modern
requirements is their constant qualiﬁcation growth although
in some cases pharmacists do not realize the importance of
advanced training. In particular, there is evidence concerning
the effect of advanced training reﬂected in the employment his-
tory on the competency of pharmacists. Pharmacists with work
experience from 0.1 to 21 years took part in the investigation,
which was held in the UK. The results showed that registration
of certiﬁcates of professional development didn’t inﬂuence
pharmacist’s activity. The most experienced participants of
the investigation could less explain changes in their practical
activity after trainings. The conclusion about the necessity of
further investigations into the role clariﬁcation of the self-reg-
ulatory pharmacist’s behavior was made [12]. In Scotland, 543
pharmacists took part in the investigation into time recording
spent on advanced training. It has been shown that 9.8% of
respondents have never passed advanced training. According
to the sector of employment the rest of the respondents spent
on average from 45 to 68 h for their qualiﬁcation improvement
[13]. The complex study as to relationship assessment of phar-
macists’ professional development has shown that such events
are not approved by pharmaceutical community everywhere
and not exclusively, especially in cases of qualiﬁcation recheck-
ing. Totally 22 works made from 2000 to 2010 were included
into analysis in the UK [14]. Canadian researchers consider
intra- and interdisciplinary cooperation necessary in conduct-
ing activities to advanced training of specialists working in
the health care system [15]. It has been shown that two main
motivational factors of curricula among students of pharmacy
higher schools were knowledge and experience gaining, as well
as a wish to get special skills [16]. These data clearly testify that
not all events as to pharmacists advanced training are neces-
sary and useful to subjects of such interaction.
The ﬁrst step toward development of pharmacogenetic test
protocols introduction into clinical practice was made in 2001,
when with antidepressant administration, physicians began to
recommend genotyping of the cytochrome gene CYP2D6.
However, in spite of the early optimism, an up to date pharma-
cogenetic test is limited by the use of only a few clinical direc-
tions, in particular, cancer and psychiatry [17]. It is important
to understand that before the introduction of a speciﬁc
pharmacogenetic test into medical practice, it is necessary to
conduct randomized clinical trials to evaluate its suitability
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use and educational programs for the corresponding specialists
[18]. Similar clinical studies have been performed for some
drugs, particularly for warfarin [19]. In some cases, a personal-
ized approach for one disease should include a number of
pharmacogenetic tests because the disease is multifactorial;
for instance, typing of several genes related to treatment of
schizophrenia [20].
Thus, on the basis of the world experience analysis concern-
ing modern biopharmaceutical technology introduction with
the aim of personalized medicine, we can make a conclusion
about a multifaceted and signiﬁcant role of a pharmacist in
the system organization, providing pharmaceutical service to
the population and developing the accurate algorithm. Further
investigations propose in-depth analysis of the situation in
Ukraine with the aim of the possibility of the country’s phar-
macogenetic infrastructure development. The range of prob-
lems presented conﬁrmed by visual examples determines the
vector and the prospects for further studies of the population
genetic structure in relation to pharmacogenetic signiﬁcant fea-
tures connected with the therapeutic efﬁciency of narcotic drug
administration among the polyethnic local population in order
to improve the quality of pharmaceutical services.
The aim of the present work is to analyze the students’
awareness about pharmacogenetics in the National University
of Pharmacy (NUPh).
2. Subjects and methods
2.1. Design and questionnaire
Field investigations were used in this work. Questioning of
NUPh students (Kharkov, Ukraine) was conducted. The ques-
tionnaire consisted of two parts: socio-demographic and basic.
In the socio-demographic part of the questionnaire there was
information about sex, age, address, educational level,
respondents’ profession and number of people in his/her fam-
ily working in the ﬁeld of health care system. The basic part of
the questionnaire consisted of the questions directed to
understanding of the role of the genetic factor in the process
of pharmacocorrection. Only some questions of the basic part
of the questionnaire have been used for the current analysis.
2.2. Subjects
Gathering of information was conducted taking into consider-
ation the ethical requirements while working with a human.
All the participants of the study gave informed consent to
anonymous questioning. The work was carried out in
accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments
involving humans.
The material analysis based on questioning 637 students of
the 1st–4th year majoring in pharmacy and studying some top-
ics on human genetics and pharmacogenetics in the ‘‘Biology
and Genetics Principles’’ course (the ﬁrst year) has been car-
ried out. According to the speciﬁc character of studying, the
contingent selection has been shifted to female side. Among
the students questioned there were 557 females (87.4%) and
80 males (12.6%). The age of the students questioned is from
17 to 23 years. In different age groups females and males werepresented as: 17 years old – 7.5% and 11.5%, 18 years old –
31.2% and 25.0%, 19 years old – 28.7% and 25.3%, 20 years
old – 18.7% and 27.5%, 21 years old – 10% and 10.2%,
22 years old – 2.5% and 0.5%, 23 years old – 1.2% and 0%,
respectively. 98.8% of males and 99.5% of females questioned
lived in Ukraine (the rest of the respondents lived in Russia
and Kazakhstan or stayed in Ukraine temporarily).
Among males, 46.4% lived in large cities with a population
of more than 1 million people, 34.5% – in big towns (popula-
tion of 250–500 thousand) and in towns (population of 100–
250 thousand), and 19.1% – in small towns (up to 50 thou-
sand) and in rural areas. Among the females questioned,
41.7% lived in large cities, 38.5% in big towns and 19.8% in
small towns and rural areas.
38.1% of the males and 42.4% of the females questioned
have family members, who work in the ﬁeld of medicine or
pharmacy.
2.3. Statistical analysis
The relationship between qualitative characteristics was evalu-
ated using the criterion v2. Conclusions to statistic hypotheses
were made at a signiﬁcance level of p 6 0.05. Microsoft Excel
and Statistica 6.1 programs were used in the study.
3. Results and discussion
Basic socio-demographic characteristics of males and females
selection were put together. Therefore, any signiﬁcant
differences could be stipulated only by sex of an individual.
As many atypical human reactions to drugs are due to a
genetic factor, it is reasonable to include the question about
the possibility of pharmacocorrection for understanding
hereditary conditions (diseases). The results of the study
showed that the majority of the males questioned believed that
it was impossible to correct hereditary diseases using drugs
(51.2%). 41.4% of females thought that hereditary diseases
could be treated with drugs (Fig. 1). Nevertheless, any signiﬁ-
cant differences between peculiarities of females’ and males’
answers to this question haven’t been found (v2 = 2.70,
m= 2, p= 0.26).
Analyzing answers to the question about the notion of
pharmacogenetics it has been shown that this concept is under-
stood differently by males and females (Table 1), and differ-
ences obtained are statistically important (v2 = 13.84, m= 6,
p= 0.03). Thus, 11.8% of the males and 6.4% of the females
questioned have not heard anything about pharmacogenetics.
14.1% of the males and of the females 25.2% have heard about
it, but do not know exactly what pharmacogenetics studies.
The right answer about the notion of pharmacogenetics was
given by one third of the males (37.7%) and females
questioned (43.9%).
Unfortunately, up to date even in developed countries
health professionals, including pharmacists, do not have sufﬁ-
cient knowledge of the correct drug administration and dosing,
as well as interact ineffectively with colleagues (physicians,
genetic consultants, etc.) [21]. However, there is a positive
experience of gradual pharmacogenetic test introduction into
practical medicine. Thus, a pilot program of the personalized
approach to clopidogrel antiplatelet administration consisted
of two stages. At ﬁrst, patients visiting a pharmacist for a
Figure 1 Analysis of the possibility of hereditary diseases’ pharmacocorrection among males and females.
Table 1 Distribution of answers to the question ‘‘What does pharmacogenetics study?’’among respondents of different sex.
Sex What does pharmacogenetics study?
Don’t
know
Have heard, but
can’t say exactly
Hereditary
diseases
The inﬂuence of
drugs on a human
Gene impact
on drugs
The possibility of
gene mutation appearance
as a result of drug administration
The body’s response
to drugs due to its
genetic peculiarities
Male (%) 11.8 14.1 17.6 3.5 4.7 10.6 37.7
Female (%) 6.4 25.2 9.7 4.5 3.6 6.7 43.9
Note. v2 = 13.84, m= 6, p= 0.03.
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test. After receiving the consent, a specialist conducts a non-
invasive collection procedure of the biological material (buccal
epithelium of the oral cavity) for genotyping of the cytochrome
gene CYP2C19, which is responsible for metabolism of the
corresponding compound. After receiving the test results, the
pharmacist got the results’ interpretation from a physician
and properly selected a dose for the patient [22]. In Spain,
the monitoring protocol of anticonvulsants, including the cor-
responding pharmacogenetic tests, have been developed and
approved [23]. The pharmacogenetic test in one of the U.S.
clinics included 136 corresponding analyses performed within
the year. Conducting educational seminars for pharmacists
was included into organizational activities. Pharmacogenetic
monitoring developed was smoothly integrated into the phar-
macokinetic control system of the clinic. The results of phar-
macogenetic tests were sent to a coordinating pharmacist,
who had to give a written interpretation of analysis and to
select the individual’s treatment [24]. In some cases besides a
positive description of the pharmacogenetic experience,
attempts of the economic efﬁciency of pharmacogenetic testing
are needed to be undertaken to assess a reduction of adverse
reactions frequency, particularly, when administering warfarin
[25].
In our study it has been stated that females – future phar-
macists are more progressive as to awareness of pharmacoge-
netics ideas. Consequently, as females are more informed
about genetic peculiarities of the organism and its response
to drugs, they probably will advise visitors of the chemist’s
to conduct these tests in future. Besides, females as a subject
of the pharmaceutical market potentially more often can be
consumers of its production themselves (according to pharma-
cogenetics tests), therefore, with their knowledge they are less
likely to have side effects due to incorrect treatment. In con-
nection with this, the male population can be classiﬁed aspotential risk group of increased frequency of atypical
reactions.
When studying the information sources concerning phar-
macogenetics it has been shown that most students received
information about this notion in the University. Moreover,
any signiﬁcant differences between males and females have
not been found (v2 = 2.23, m= 5, p= 0.82). In particular,
the curriculum for the discipline ‘‘Biology and Genetics princi-
ples’’ for the 1st year students of specialty ‘‘Pharmacy’’ in
NUPh pays some attention to pharmacogenetics; it considers
topics related to population genetics and hereditary diseases.
According to the questionnaire data 70.7% of males and
72.9% of female respondents heard about pharmacogenetics
superﬁcially in University; 13.4% of males and 10.5% of
females knew nothing about this notion at all (Table 2).
For discussion, one can give some examples about the spe-
cialists’ awareness of pharmacogenetics and pharmacogenetics
testing and related questions in some other samples.
New biotechnological approaches of study in pharmaceu-
tics are differently treated by pharmacists. 580 U.S. pharma-
cists expressed positive attitudes toward pharmacogenetic
testing at on-line questioning. The majority of the participants
questioned (87%) thought that this diagnostic procedure pro-
motes a decrease in the number of adverse reactions, and opti-
mization of the drug dose. More than half of the participants
questioned (57%) thought that patient consulting and explain-
ing the results of pharmacogenetic tests to them were included
in their tasks. At the same time the majority of the participants
questioned (65%) expressed the apprehension that pharmaco-
genetic tests could be used with the aim of medical insurance
annulation [26]. For comparison, we can use the results of
questionnaires conducted in the USA among genetic consul-
tants and clinical geneticists. It has been shown that 12% of
genetic consultants and 41% of clinical geneticists promoted
pharmacogenetic test conducting in patients; it is a relatively
Table 2 Distribution of answers to the question ‘‘Where did you get information about pharmacogenetics?’’ among males and
females.
Sex The source of information about pharmacogenetics
Don’t have any
information
Have heard in
University
(superﬁcially)
Studied in
University
(as a discipline)
Got to know
from friends
Got to know
from media
Male (%) 13.4 70.7 3.7 3.7 8.5
Female (%) 10.5 72.9 5.6 4.9 6.1
Note. v2 = 2.23, m= 5, p= 0.82.
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Almost all questioned participants had an idea about
pharmacogenetic, although only 28% of consultants and
58% of clinical geneticists were well prepared in the ﬁeld of
pharmacogenetic testing. About half of genetic consultants
(52%) and clinical geneticists (46%) thought that introduction
of a pharmacogenetic test into clinical practice was their task,
although 17% and 19% of the participants questioned from
these groups did not consider this activity as a component of
their work [27]. Explanatory work, accessible students and
practising pharmacists’ education on speciﬁc pharmacogenetic
methods, particularly warfarin dosing on the basis of the
patient genotyping, have shown high effectiveness. So, the
competence level of the participants under study determined
after ﬁlling test sheets was 97 ± 3%. Thus, even short training
courses may be effective for personalized diagnostics and inter-
pretation of pharmacogenetic test results [28]. Other authors
studied the effectiveness of advanced training on pharmacoge-
netics, which was taught to 272 pharmacists within 2 months.
However, the investigation results showed that the average
improvement was only 0.7 points on the test system of 11 ques-
tions of multiple-choice [29]. Questioning of 284 Canadian
practicing pharmacists regarding their pharmacogenetics
vision and its role in the introduction into medical practice
has shown that more than 95% are ready to recommend con-
ducting pharmacogenetic tests to potential customers, but only
a small number of respondents (7.7%) had the necessary
knowledge for this. Majority of pharmacists (96.6%) showed
the necessity of additional pharmacogenetic training [30].
The cross-sectional study of the Australian pharmacists
showed their weak background in the pharmacogenetic ﬁeld.
An inverse relationship between awareness level and work
experience was found. Thus, pharmacists with the greatest
work experience had less knowledge relative to pharmacoge-
netic testing. Most respondents thought that it was more
optimal to conduct the corresponding courses and seminars
while studying at the University, but not in the post graduate
system of studying and advanced training [31]. Available data
as to the patients’ relation to pharmacogenetic testing in gen-
eral showed their concern. A randomized telephone question-
ing of the US population revealed that 90% of the
respondents were extremely positive about the possibility that
the medical personal would have their results of pharmacoge-
netic tests. Fewer respondents questioned (74%) approved
such results provided by pharmacists [32]. Questioning of
people suffering from chronic diseases or having sick family
members showed a positive attitude toward pharmacogenetictests conducting and most have the complete awareness of
physicians and pharmacists [33].
Our analysis has shown that even among future pharma-
cists the awareness about pharmacogenetics and its role in per-
sonalized medicine is not satisfactory both in Ukraine and
other countries. Thus, it is necessary to pay more attention
to the aspects of pharmacogenetics when training competent
up to date specialists in the ﬁeld of pharmacy. Effective devel-
opment of the appropriate infrastructure in pharmacogenetics
testing and its introduction among the population of Ukraine
are also necessary.4. Conclusion
The analysis of the future pharmacists’ awareness in the ﬁeld
of genetics and pharmacogenetics, as well as the study of the
sex speciﬁcity of this awareness, has been carried out for the
ﬁrst time in Ukraine. It has been stated that more than 70%
of the students questioned got the information about pharma-
cogenetics in University for the ﬁrst time. However, only more
than one-third of respondents (37.7% of males and 43.9% of
females) correctly understand the idea of this discipline. About
half of the students questioned thought that pharmacocorrec-
tion of hereditary diseases was impossible. It has been shown
that on the whole females were more informed about pharma-
cogenetics than males. So, they can become more active per-
sons of pharmaceutical market in future.
Acknowledgments
Authors are grateful to the rector of NUPh, corr-mem. of the
NAS of Ukraine, Prof. V.P. Chernykh; the head of Depart-
ment of Human Physiology and Anatomy, Prof. L.N. Malosh-
tan; the head of Department of Microbiology, Virology and
Immunology, Prof. N.I. Filimonova; the head of Department
of Pharmacology, Prof. S.Yu. Shtrygol; the head of Depart-
ment of Management and Marketing in Pharmacy, Prof.
V.V. Malyi for their assistance in conducting this research.
References
[1] Vizirianakis IS. Pharmaceutical education in the wake of genomic
technologies for drug development and personalized medicine.
Eur J Pharm Sci 2002;15(3):243–50.
[2] van Puijenbroek E, Conemans J, van Grootheest K. Spontaneous
ADR reports as a trigger for pharmacogenetic research: a
66 O.V. Filiptsova et al.prospective observational study in the Netherlands. Drug Saf
2009;32(3):255–64.
[3] Alnaim L. Therapeutic drug monitoring of cancer chemotherapy.
J Oncol Pharm Pract 2007;13(4):207–21.
[4] Beier MT, Panchapagesan M, Carman LE. Pharmacogenetics: has
the time come for pharmacists to embrace and implement the
science? Consult Pharm 2013;28(11):696–711.
[5] Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and
DPYD: genotyping to ensure safer cancer therapy? Trends
Pharmacol Sci 2006;27(8):432–7.
[6] Frazer KA. Decoding the human genome. Genome Res 2012;22:
1599–601.
[7] Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lo¨tsch J,
Roots I, et al. Pharmacokinetics of codeine and its metabolite
morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Pharmacogenomics J 2007;7(4):257–65.
[8] Ali S, Drendel AL, Kircher J, Beno S. Pain management of
musculoskeletal injuries in children: current state and future
directions. Pediatr Emerg Care 2010;26(7):518–24.
[9] Stamer UM, Zhang L, Stu¨ber F. Personalized therapy in pain
management: where do we stand? Pharmacogenomics 2010;11(6):
843–64.
[10] Gan SH, Ismail R, Wan Adnan WA, Zulmi W. Impact of
CYP2D6 genetic polymorphism on tramadol pharmacokinetics
and pharmacodynamics. Mol Diagn Ther 2007;11(3):171–81.
[11] El-Ibiary SY, Cheng C, Alldredge B. Potential roles for pharma-
cists in pharmacogenetics. J Am Pharm Assoc 2008;48(2):21–9.
[12] Kostrzewski AJ, Dhillon S, Goodsman D, Taylor KM. The
inﬂuence of continuing professional development portfolio records
on pharmacy practice. Int J Pharm Pract 2009;17(2):107–13.
[13] Power A, Johnson BJ, Diack HL, McKellar S, Stewart D, Hudson
SA. Scottish pharmacists’ views and attitudes towards continuing
professional development. Pharm World Sci 2008;30(1):136–43.
[14] Donyai P, Herbert RZ, Denicolo PM, Alexander AM. British
pharmacy professionals’ beliefs and participation in continuing
professional development: a review of the literature. Int J Pharm
Pract 2011;19(5):290–317.
[15] Fleet LJ, Kirby F, Cutler S, Dunikowski L, Nasmith L,
Shaughnessy R. Continuing professional development and social
accountability: a review of the literature. J Interprof Care 2008;
22(1):15–29.
[16] Bucci KK, Knapp KK, Ohri LK, Brooks PJ. Factors motivating
pharmacy students to pursue residency and fellowship training.
Am J Health Syst Pharm 1995;52(23):2696–701.
[17] Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der
Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte–
an update of guidelines. Clin Pharmacol Ther 2011;89(5):662–73.
[18] Shin J, Kayser SR, Langaee TY. Pharmacogenetics: from discov-
ery to patient care. Am J Health Syst Pharm 2009;66(7):625–37.
[19] Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S,
Nicholas ZP, et al. Randomized trial of genotype-guided versusstandard warfarin dosing in patients initiating oral anticoagula-
tion. Circulation 2007;116(22):2563–70.
[20] Wilffert B, Zaal R, Brouwers JR. Pharmacogenetics as a tool in
the therapy of schizophrenia. Pharm World Sci 2005;27(1):
20–30.
[21] Nickola TJ, Green JS, Harralson AF, O’Brien TJ. The current
and future state of pharmacogenomics medical education in the
USA. Pharmacogenomics 2012;13(12):1419–25.
[22] O’Connor SK, Ferreri SP, Michaels NM, Greco AJ, Viera AJ,
Faruki H, et al. Exploratory planning and implementation of a
pilot pharmacogenetic program in a community pharmacy.
Pharmacogenomics 2012;13(8):955–62.
[23] Aldaz A, Ferriols R, Aumente D, Calvo MV, Farre MR, Garcia
B, et al. Pharmacokinetic monitoring of antiepileptic drugs. Farm
Hosp 2011;35(6):432–7.
[24] Crews RK, Cross ShJ, McCormick JN, Baker DK, Molinelli AR,
Mullins R, et al. Development and implementation of a phar-
macist-managed clinical pharmacogenetics service. Am J Health
Syst Pharm 2011;68(2):143–50.
[25] Mahajan P, Meyer KS, Wall GC, Price HJ. Clinical applications
of pharmacogenomics guided warfarin dosing. Int J Clin Pharm
2013;35(3):359–68.
[26] Tuteja S, Haynes K, Zayac C, Sprague JE, Bernhardt B, Pyeritz
R. Community pharmacists’ attitudes towards clinical utility and
ethical implications of pharmacogenetic testing. Per Med
2013;10(8).
[27] Haga SB, O’Daniel JM, Tindall GM, Mills R, Lipkus IM, Agans
R. Survey of genetic counselors and clinical geneticists’ use and
attitudes toward pharmacogenetic testing. Clin Genet 2012;82(2):
115–20.
[28] Drozda K, Labinov K, Jiang R, Thomas MR, Wong SS, Patel S,
et al. A pharmacogenetics service experience for pharmacy
students, residents, and fellows. Am J Pharm Educ 2013;77(8):175.
[29] Formea CM, Nicholson WT, McCullough KB, Berg KD, Berg
ML, Cunningham JL, et al. Development and evaluation of a
pharmacogenomics educational program for pharmacists. Am J
Pharm Educ 2013;77(1):10.
[30] de Denus S, Letarte N, Hurlimann T, Lambert JP, Lavoie A,
Robb L, et al. An evaluation of pharmacists’ expectations
towards pharmacogenomics. Pharmacogenomics 2013;14(2):
165–75.
[31] McMahon T, Tucci J. The perceptions of pharmacists in Victoria,
Australia on pharmacogenetics and its implications. Pharm Pract
(Granada) 2011;9(3):141–7.
[32] Haga SB, Kawamoto K, Agans R, Ginsburg GS. Consideration
of patient preferences and challenges in storage and access of
pharmacogenetic test results. Genet Med 2011;13(10):887–90.
[33] Haddy CA, Ward HM, Angley N, McKinnon RA. Consumers’
views of pharmacogenetics – a qualitative study. Res Social Adm
Pharm 2010;6(3):221–31.
